SciBase Announces Rights Issue to Raise Approximately 83 Million SEK for US Operations
SciBase Announces Rights Issue to Raise Approximately 83 Million SEK for US Operations
The Board of Directors of SciBase Holding AB has made a significant decision to proceed with a rights issue aiming to raise approximately SEK 83 million. This strategic move, which comes after the authorization granted at the Annual General Meeting in June 2025, is intended to bolster the company’s commercialization efforts, particularly in the US market.
Overview of the Rights Issue
On January 8, 2026, existing shareholders will receive one subscription right for each share they own, which will allow them to purchase a new share at a price of SEK 0.20. The rights issue is substantially backed by subscription commitments totaling about SEK 64.3 million, reflecting a solid confidence from investors, with about 77.6% of the rights issue already covered. The subscription period is set from January 12 to January 26, 2026.
Rationale Behind the Move
SciBase is well-known for its innovative work in dermatology, particularly through its product Nevisense, which integrates artificial intelligence with Electrical Impedance Spectroscopy, enhancing the diagnostic accuracy of skin diseases. The company has established a strong presence in the German market, with over 400 units installed, generating recurring revenues exceeding SEK 20 million annually. However, expansion into the US market has gained momentum since 2024, witnessing a staggering revenue increase of over 200% in the first nine months of 2025 alone.
To achieve its operational breakeven, SciBase aims to install 800 to 1,000 systems in the US, complemented by its already active systems in Germany. The rights issue intends to fuel these initiatives and sustain operations until at least 2027. This financial boost is also geared towards forthcoming expansions into nearby markets such as Austria, Switzerland, and Italy.
Collaboration with Castle Bioscience
In June, SciBase partnered with Castle Bioscience for advancing additional skin disease diagnostics, particularly focusing on atopic dermatitis. This collaboration has progressed effectively, with plans to expedite operations across further indications. Castle Bioscience has also provided a long-term loan facility, ensuring adequate resources to increase production capabilities to meet demand for Nevisense systems.
Timeline and Important Dates
Key dates in the rights issue process are as follows:
- - Last trading day for shares with subscription rights: January 5, 2026
- - First trading day for shares excluding subscription rights: January 7, 2026
- - Subscription period: January 12 to January 26, 2026
- - Expected announcement of the rights issue outcome: January 27, 2026
Conclusion
The upcoming rights issue presents an exciting opportunity for existing shareholders to increase their stake in SciBase as it continues its journey to enhance diagnostic efficacy in dermatology. Given the company’s innovative solutions and strong growth trajectory, this capital injection could significantly accelerate its objectives in the highly lucrative US market and beyond. For additional information and updates, shareholders and potential investors should consider monitoring SciBase’s official statements and public disclosures leading up to the rights issue.
SciBase's emphasis on early detection through technology stands to minimize patient suffering and improve healthcare outcomes, reinforcing its commitment to transforming the dermatological landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.